PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Ophthalmic Surg Lasers Imaging. Author manuscript; available in PMC 2010 July 20.
Published in final edited form as:
Ophthalmic Surg Lasers Imaging. 2007 Sep–Oct; 38(5): 423–428.
PMCID: PMC2907252
NIHMSID: NIHMS84288

High-speed, Ultrahigh Resolution Optical Coherence Tomography of the Retina in Hunter Syndrome

Abstract

A 42-year-old man with Hunter syndrome developed bilateral visual field loss. Visual field testing demonstrated bilateral ring scotomata that corresponded to areas of thinning seen on standard resolution optical coherence tomography. High-speed, ultrahigh resolution optical coherence tomography, capable of 3.5-micron axial resolution, showed a loss of photoreceptors outside the fovea and cystoid spaces within the inner nuclear, ganglion cell, and outer nuclear layers. These results were consistent with histopathologic features that have been reported previously in patients with Hunter syndrome. Optical coherence tomography could be used as a diagnostic modality to monitor patients with Hunter syndrome and to detect subclinical forms of disease.

INTRODUCTION

The lysosomal storage disease, Hunter syndrome or mucopolysaccharidosis type II, results from the X-linked inherited deficiency of the enzyme iduronate 2-sulfatase. Progressive dermatan sulfate and heparan sulfate accumulation in all tissues of the body leads to multiple systemic problems, including cardiac abnormalities, hepatosplenomegaly, and progressive deafness.

Ocular manifestations of Hunter syndrome include exophthalmos, hypertelorism, and pigmentary retinopathy. Unlike other lysosomal storage diseases, patients with Hunter syndrome typically exhibit clear corneas. Histopathologic and electron microscopic reports show retinal abnormalities similar to retinitis pigmentosa, including the loss of photoreceptors peripherally and the migration of retinal pigment epithelial pigment into the retinal layers.1

The following case is an example of Hunter syndrome imaged with high-speed, ultrahigh resolution optical coherence tomography (OCT), which is capable of 3.5-micron axial resolution in the human eye2 in comparison to 8- to 10-micron axial resolution of Stratus OCT (Carl Zeiss Meditec, Dublin, CA).3

CASE REPORT

A 42-year-old man with Hunter syndrome was referred to our institution for evaluation of bilateral visual field loss. During the past few years, he had noticed difficulty seeing pedestrians while driving. On ophthalmic examination, his visual acuity was 20/30 in the right eye and 20/25 in the left eye. His corneas were clear bilaterally. Fundus examination showed normal-appearing retinas with no pigmentary changes. Both optic nerve heads were slightly crowded (Figs. 1A and 1B). Visual field testing (30-2 full-threshold test with the Humphrey Visual Field Analyzer [Carl Zeiss Meditec]) showed bilateral ring scotomata (Figs. 1C and 1D). Hertel exophthalmometry was 23 mm on the right and 21 mm on the left. Fluorescein angiography revealed choroidal folds in the left eye (Fig. 2A).

Figure 1
(A, B) Color fundus photographs showing slightly crowded optic nerve heads. The posterior pole of the retina shows no pigmentary defects. (C, D) Automated perimetry showing ring scotomata in the right and left eye, respectively.
Figure 2
(A) Fluorescein angiography of the left eye showing superotemporal choroidal folds with some staining of the temporal perifoveal region. (B) Horizontal Stratus OCT (Carl Zeiss Meditec, Dublin, CA) of the left eye revealing small foveal and parafoveal ...

Multifocal electroretinography (Visual Evoked Response Image System; EDI, Inc., Burlingame, CA) showed a reduction in foveal responses bilaterally. There were decreased amplitudes throughout the 25° test area.

The retina was scanned with Stratus OCT. The retinal nerve fiber layer showed normal thickness around both optic nerve heads. Macular OCT showed generalized thinning of the retinas, most pronounced in the 3.0- to 6.0-mm ring around the foveae. In addition, small foveal and parafoveal cystoid spaces were seen in the inner retina bilaterally (Fig. 2B).

High-speed, ultrahigh resolution OCT showed several small hyporeflective cystoid spaces in the ganglion cell layer, inner nuclear layer, and outer nuclear layer bilaterally (Fig. 2C). Retinal thickness measurements were obtained using a radial scan protocol of 24 images centered on the foveola. Each image consisted of 1,500 axial scans. The outer retina was significantly thinned, especially outside a 1.5-mm diameter ring around the fovea (Fig. 3). The external limiting membrane was hyperreflective centrally, whereas the inner segment–outer segment photoreceptor junction could not be visualized beyond the parafovea. The hyperreflective band corresponding to the retinal pigment epithelium and photoreceptor outer segment tips appeared slightly thickened in the center bilaterally.

Figure 3
Segmentation of high-speed, ultrahigh resolution optical coherence tomography (OCT) images of the right eye. (A) Fundus photograph demonstrating measurement areas. Circle diameters are 0.75, 1.5, 2.25, and 3.0 mm. (B) High-speed ultrahigh resolution OCT ...

DISCUSSION

Several histopathologic and electron micrographic studies of the eye have been performed in patients with Hunter syndrome.1,4,5 All of these patients suffered from a more severe form of Hunter syndrome (mucopolysaccharidosis type IIa) in which death occurs before 35 years of age. Perhaps the most striking feature in these cases was photoreceptor degeneration with pigment migration into the retina.

This histopathologic appearance has been considered to be identical to retinitis pigmentosa despite the lack of characteristic findings on clinical examination, such as bone spicule pigmentation.6 One previous histopathologic report of Hunter syndrome described widespread loss of the retinal pigment epithelium and loss of the overlying photoreceptors.4 There have been no histopathologic descriptions of the retinas from patients with the mild form of Hunter syndrome.

Our patient experienced ocular symptoms typical of Hunter syndrome. He was both exophthalmic and hyperteloric, and he did not exhibit any corneal clouding. His pattern of visual field loss, with symmetric bilateral ring scotomata, suggested a significant degree of extrafoveal photoreceptor loss with central sparing. Consistent with previous electroretinographic reports, our patient had a mild bilateral reduction in foveal responses on multifocal electroretinographic testing.7,8

Optic disc swelling has been described in a patient with Hunter syndrome in whom a histopathologic study revealed a grossly thickened posterior sclera with secondary compression of the optic nerve head.9 Our patient did have crowded discs on clinical examination and on retinal nerve fiber layer analysis with OCT. Furthermore, choroidal folds were seen in the left eye. These findings may have been secondary to infiltration of the sclera by mucopolysaccharides.

Standard resolution OCT showed a thinning pattern that corresponded to our patient’s visual field impairments. Each of the nine sectors on the macular thickness map showed thinning compared with normal eyes,10 but the effects were most pronounced in the outer perifoveal ring. There also appeared to be small cystoid structures in the inner foveal and parafoveal retina of both eyes. Further localization of the cystoid spaces was not possible due to limited image resolution.

High-speed, ultrahigh resolution OCT provided more detailed images of the retina. The outer nuclear layer was attenuated, consistent with a previous histopathologic report of Hunter syndrome.4 There was marked thinning of the photoreceptor layer bilaterally. The external limiting membrane was surprisingly prominent in the foveal region, possibly reflecting the deposition of glycosaminoglycans. Peripherally, the photoreceptor inner segment–outer segment junction could not be distinguished from the retinal pigment epithelium, a sign of significant photoreceptor atrophy. Thickness measurements from the retinal pigment epithelium to the boundary of the photoreceptor inner segment–outer segment junction confirmed photoreceptor outer segment thinning, most pronounced outside a 1.5-mm diameter ring around the fovea. Beyond this ring, the photoreceptor inner segment–outer segment junction could not even be visualized.

A previous report using ultrahigh resolution OCT in patients with retinitis pigmentosa demonstrated similar atrophy of the photoreceptor layer in the extrafoveal retina.11 In our case, the outer hyperreflective band corresponding to the retinal pigment epithelium and the tips of the photoreceptor outer segments appeared thickened centrally, possibly indicating retinal pigment epithelium hyperplasia, as described in a previous histopathologic study.5 Despite the mild clinical phenotype of our patient, these high-speed, ultrahigh resolution OCT findings correlated with the histopathologic findings of more severe forms of Hunter syndrome.

Several histopathologic reports of Hunter syndrome have shown multiple membranous lamellar vacuoles in the cytoplasm of retinal ganglion cells.1,4,5 With high-speed, ultrahigh resolution OCT, we were able to clearly localize several cystoid spaces to the inner nuclear, ganglion cell, and outer nuclear layers. The sizes of these spaces ranged from approximately 30 to 60 microns in depth and almost 100 microns in width. The composition of these spaces remains unknown, although they are likely intracellular collections of glycolipids that have been described histologically. We detected no evidence of vitreous bodies, cystic macular edema, or vitreoretinal interface abnormalities, all findings that have been shown by standard resolution OCT in one patient with Hunter syndrome.12

In July 2006, the U.S. Food and Drug Administration approved a new medication, idursulfase, as the first treatment for Hunter syndrome. In one study, this human enzyme replacement therapy has been shown to improve ambulation in patients who received weekly infusions.13 We do not yet know whether a correlation exists between macular thickness measured by OCT and treatment with idursulfase, but OCT could potentially identify structural markers for treatment response. Although the diagnosis of Hunter syndrome is made by detection of elevated levels of dermatan and heparan sulfate in the urine and confirmed by detection of enzyme deficiency in fibroblasts, OCT might be used as a modality to detect subclinical disease.

High-speed, ultrahigh resolution OCT findings in our patient were consistent with histopathologic and ultrastructural features that have been reported previously in patients with Hunter syndrome. The OCT changes also correlated with visual field and electro-retinographic testing. Because OCT is noninvasive, reproducible, and easy to perform, it could be used to monitor patients with Hunter syndrome, especially as new treatments become available.

Acknowledgments

Supported in part by National Institutes of Health RO1-EY13178-06, RO1-EY11289-20, P30-EY08098, P30-EY13078, Air Force Office of Scientific Research, Medical Free Electron Laser Program contract FA9550-040-1-0046, FA9550-040-1-0011, National Science Foundation ECS-0119452, BES-0522845, The Eye and Ear Foundation (Pittsburgh, PA), and Research to Prevent Blindness Unrestricted Grant and Medical Student Eye Research Fellowship.

Drs. Fujimoto and Schuman receive royalties from intellectual property licensed by the Massachusetts Institute of Technology to Carl Zeiss Meditec, and Drs. Duker and Schuman receive research support from Optovue, Inc. Dr. Schuman also receives research support from Alcon Laboratories, Inc., Allergan, Inc., SOLX, and Clarity, and receives lecture fees from Alcon Laboratories, Inc., Allergan, Inc., Carl Zeiss Meditec, Merck U.S. Human Health, the National Eye Institute, Heidelberg Engineering, Inc., and Optovue, Inc.

Dr. Schuman did not participate in the editorial review of this manuscript.

REFERENCES

1. McDonnell JM, Green WR, Maumenee IH. Ocular histopathology of systemic mucopolysaccharidosis, type II-A (Hunter syndrome, severe) Ophthalmology. 1985;92:1772–1779. [PubMed]
2. Srinivasan V, Wojtkowski M, Witkin AJ, et al. High-definition and 3-dimensional imaging of macular pathologies with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology. 2006;113:2054, e1–e14. [PMC free article] [PubMed]
3. Fujimoto JG, Huang D, Hee MR, et al. Physical properties of optical coherence tomography. In: Schuman JS, Puliafito CA, Fujimoto JG, editors. Optical Coherence Tomography of Ocular Diseases. 2nd ed. Thorofare, NJ: SLACK Incorporated; 2004. pp. 677–688.
4. Goldberg MF, Duke JR. Ocular histopathology in Hunter’s syndrome: systemic mucopolysaccharideosis type II. Arch Ophthalmol. 1967;77:503–512. [PubMed]
5. Topping TM, Kenyon KR, Goldberg MF, Maumenee AE. Ultrastructural ocular pathology of Hunter’s syndrome: systemic mucopolysaccharideosis type II. Arch Ophthalmol. 1971;86:164–177. [PubMed]
6. To K, Adamian M, Dryja TP, Berson EL. Retinal histopathology of an autopsy eye with advanced retinitis pigmentosa in a family with rhodopsin Glu181Lys. Am J Ophthalmol. 2000;130:790–792. [PubMed]
7. Abraham FA, Yatziv S, Russell A, Auerbach E. Electrophysiological and psychophysical findings in Hunter syndrome. Arch Ophthalmol. 1974;91:181–186. [PubMed]
8. Caruso RC, Kaiser-Kupfer MI, Muenzer J, Ludwig IH, Zasloff MA, Mercer PA. Electroretinographic findings in the mucopolysaccharidoses. Ophthalmology. 1986;93:1612–1616. [PubMed]
9. Beck M, Cole G. Disc oedema in association with Hunter’s syndrome: ocular histopathological findings. Br J Ophthalmol. 1984;68:590–594. [PMC free article] [PubMed]
10. Chan A, Duker JS, Ko TH, Fujimoto JG, Schuman JSS. Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography. Arch Ophthalmol. 2006;124:193–198. [PMC free article] [PubMed]
11. Ko TH, Fujimoto JG, Schuman JS, et al. Comparison of ultrahigh- and standard-resolution optical coherence tomography for imaging macular pathology. Ophthalmology. 2005;112:1922–1922. e1–e15. [PMC free article] [PubMed]
12. Anawis MA. Hunter syndrome (MPS II-B): a report of bilateral vitreous floaters and maculopathy. Ophthalmic Genet. 2006;27:71–72. [PubMed]
13. Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase therapy in mucopolysaccharidosis II (Hunter syndrome) Genet Med. 2006;8:465–473. [PubMed]